Eric Lifesciences has acquired Strides’ India branded generics business for an aggregate cash consideration of Rs 500 crore..Shardul Amarchand Mangaldas advised Eric Lifesciences and the team was led by Partners Amit Khansaheb and Roshan Thomas, along with Senior Associates Prateek Lala and Hardik Bhatia and Associates Alekhya Donepudi, Christopher Rao and Rimjhim Khandelwal..Tatva Legal acted for Strides Shasun with a team led by NK Dilip..Strides’ India branded generics business comprise of a portfolio of 130+ brands in the domains of Neurology, Psychiatry, Nutraceuticals, Gastro etc. along with the employees forming part of the business..Post-acquisition Eris will break into the league of top 25 companies having a market share of more than 1% in the Indian Pharmaceutical Market, reported Business Standard.
Eric Lifesciences has acquired Strides’ India branded generics business for an aggregate cash consideration of Rs 500 crore..Shardul Amarchand Mangaldas advised Eric Lifesciences and the team was led by Partners Amit Khansaheb and Roshan Thomas, along with Senior Associates Prateek Lala and Hardik Bhatia and Associates Alekhya Donepudi, Christopher Rao and Rimjhim Khandelwal..Tatva Legal acted for Strides Shasun with a team led by NK Dilip..Strides’ India branded generics business comprise of a portfolio of 130+ brands in the domains of Neurology, Psychiatry, Nutraceuticals, Gastro etc. along with the employees forming part of the business..Post-acquisition Eris will break into the league of top 25 companies having a market share of more than 1% in the Indian Pharmaceutical Market, reported Business Standard.
